![]() Brilinta is currently approved to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina or non-ST-elevation MI or ST-elevation MI).įor more information call (800) 236-9933 or visit. Full study results will be submitted to a scientific meeting in 2015.īrilinta is a direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation. #Pegasus timi 54 trial#Both doses of Brilinta showed f statistically significant reduction in major cardiovascular thrombotic events in patients with a history of MI. Pegasus-TIMI 54 is a randomised, double-blind, three-arm, parallel-group, international, multi-centre study which is expected to examine the long-term efficacy and safety of ticagrelor in patients who have sustained a heart attack from one to three years prior to enrolment. Bench siano studi diversi, nati con razionali e finalit differenti, il trial PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart. The occurrence of major adverse cardiovascular events (MACE defined as cardiovascular death. Patients with a history of PAD at trial enrollment were included in this secondary analysis. The primary efficacy endpoint was a composite of CV death, myocardial infarction (MI) or stroke. The PEGASUS-TIMI 54 trial randomized 21,162 patients with prior MI (1-3 years) to ticagrelor 90 mg BID, 60 mg BID, or placebo in addition to low-dose aspirin. RELATED: Development of Brilinta Reversal Agent Initiated by AstraZeneca PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group) studied Brilinta 60mg twice daily or 90mg twice daily with low-dose aspirin in over 21,000 patients aged ≥50 years with a history of heart attack and one additional cardiovascular (CV) risk factor for the secondary prevention of atherothrombotic events. The PEGASUS-TIMI 54 trial inclusion criteria effectively identified high-risk patients with recent myocardial infarction (MI) who would benefit from continuing dual antiplatelet therapy (DAPT) with ticagrelor for more than 12 months. AstraZeneca announced that Brilinta (ticagrelor) met the primary endpoint in the PEGASUS-TIMI 54 study. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |